Abstract 5084
Background
Teenage and young adult cancer services in England are centralised in 13 principal treatment centres (TYA PTC). We sought to evaluate whether caregivers of young people with cancer had fewer unmet information and support needs if cancer care was provided in a TYA PTC.
Methods
Participants in the cohort study of young people with cancer nominated their main carer to complete the BRIGHTLIGHT Carer Questionnaire. Questionnaires were completed six months after diagnosis. Comparisons were made according to where young people’s care was delivered: all, some or no care in a TYA PTC. Principal component analysis reduced the questionnaire to five dimensions, which were used as dependent variables in subsequent regression analysis.
Results
A total of 830 young people were part of the BRIGHTLIGHT Cohort, of which 514 (62%) caregivers returned a questionnaire. Four hundred and seventy-six responses out of 514 returned questionnaires (92%) could be linked to the location of young people’s care and were included in the analysis. The majority of caregivers were white (89.7%), middle aged (71.1%), married/cohabiting (78%) mothers (80.2%). The Adjusted analysis indicated that caregivers of young people who had all or some of their care in a TYA PTC had more satisfaction with support and also with services specifically provided for carers. Those who had some care in a TYA PTC had greater satisfaction with information but less opportunity to be involved in decisions.
Conclusions
Caregivers of young people who had no TYA PTC, i.e. treated solely in adult or children’s cancer units have the most unmet information and support needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
UCLH.
Funding
National Institute for Health Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract